
New Research Bolsters Freaky Theory That Earth Sits in a Giant Cosmic Void
The fact is, space is likely peppered with bubbles of relative emptiness, and some astronomers believe we're sitting inside of one. A growing body of evidence suggests that our entire Milky Way galaxy is located within an enormous cosmic void. Most recently, researchers found that sound waves from the early universe—essentially the sound of the Big Bang—support this idea. This work, led by Indranil Banik, a cosmologist at the University of Portsmouth, proposes a solution for the Hubble tension: one of the biggest mysteries in the universe.
Banik and his colleagues published their findings in the journal Monthly Notices of the Royal Astronomical Society in May. He has been working on the Hubble tension for the past five years. This puzzling cosmological problem stems from two differing values calculated for the Hubble constant, which represents the expansion rate of today's universe.
'The Hubble tension is a mismatch between the rate at which we expect the universe to be expanding—based on extrapolating observations of the infant universe forward to today, using the standard cosmological model—and the rate at which we actually observe it to be expanding when we look at the nearby universe,' Banik told Gizmodo. It's really a mismatch between theory and observations.'
Basically, galaxies and stars in the local, more recent universe appear to be moving away faster than the Hubble constant predicts. This defies the standard cosmological model, which describes how the universe grows and evolves. It also throws the age of the universe into question, as astronomers need the Hubble constant to extrapolate how much time has passed since the Big Bang.
Banik believes the local void theory can offer a solution. If our galaxy is located inside a bubble of relatively empty space, gravity would pull nearby matter toward the higher density exterior of the void, he explained in a Royal Astronomical Society statement. As the void empties out, the velocity of objects moving away from us would be larger than if the void were not there, thus giving the appearance of a faster local expansion rate, Banik said.
For this to make sense, our solar system would need to be near the center of a void about two billion light-years wide with a density about 20% lower than the average density of the universe (to be clear, a void isn't just empty space—it's a region of the universe with fewer galaxies and less matter than average). This theoretical low-density region has become known as the KBC void.
Multiple studies have supported its existence, including several authored by Banik. Still, the local void theory remains controversial because the void doesn't fit with the standard model of cosmology, which states that the matter that makes up today's universe should be more uniformly spread out on such large scales. The KBC void 'is too large and too deep for the standard model of cosmology, where the chance of us randomly finding ourselves in such a void is about one in a billion,' Banik told Gizmodo. 'So we would need to adjust the model such that structure on scales beyond about one hundred million light-years grows faster than the model predicts.'
His most recent study looked at baryon acoustic oscillations (BAOs). These are a pattern of wrinkles in the density distribution of galaxy clusters spread across the universe. Banik likened them to sound waves from the Big Bang. BAOs provide an independent way to measure the expansion rate of the universe and how fast that rate has changed throughout cosmic history. These 'sound waves' act as a sort of standard ruler, and astronomers can use the ruler's angular size to chart the history of cosmic expansion, according to Banik.
He and his colleagues considered all available BAO measurements over the last 20 years. Their work showed that a local void model is about one hundred million times more likely than a standard cosmological model without a local void.
This is strong evidence to suggest that we are, indeed, living inside a cosmic void, but it isn't definitive proof. Banik is also working with supernovae data to investigate one of the main pitfalls of the local void theory. 'Any kind of local or late-time solution to the Hubble tension implies that in the more distant universe, there wasn't a Hubble tension,' he explained. 'Supernovae data seem to suggest that the Hubble tension actually does persist out to higher redshift.'
If he can find evidence to show that the Hubble tension disappears beyond the local universe, that would be a breakthrough for the local void theory. For now, though, this cosmic conundrum will remain unresolved.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Landmark Study Shows Ultromics' EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography
Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical. EchoGo® Amyloidosis is the first FDA-cleared AI screening tool for cardiac amyloidosis using an echocardiogram and has received Breakthrough Device designation from the FDA. Study results demonstrate accuracy of EchoGo® Amyloidosis in detecting cardiac amyloidosis, with strong performance across AL, ATTRwt, and ATTRv subtypes. OXFORD, England, July 9, 2025 /PRNewswire/ -- A large-scale, multi-center international study published in the European Heart Journal has shown that EchoGo® Amyloidosis, an AI-powered tool developed by Ultromics, significantly improves the screening of cardiac amyloidosis from a standard echocardiogram. It is the first FDA-cleared AI tool for this condition and has also received Breakthrough Device designation from the FDA. Researchers from Ultromics and Mayo Clinic, with investigators at The University of Chicago Medicine and collaborators around the world, validated and tested the model in a large and multiethnic patient population, and compared its performance to conventional diagnostic methods. The findings demonstrate that EchoGo® Amyloidosis is highly accurate, achieving 85% sensitivity and 93% specificity.1 The model performed consistently well across all major cardiac amyloidosis subtypes, and crucially distinguished the disease from phenotypically similar conditions such as hypertensive heart disease, HFpEF, and hypertrophic cardiomyopathy, conditions that often contribute to missed or delayed diagnosis.1 "EchoGo® Amyloidosis is a breakthrough tool that can help us identify at-risk patients so they can receive the treatment they need," said Ross Upton, CEO and Founder of Ultromics. "It uses deep learning to analyze a single routine echocardiography videoclip to deliver insights, helping clinicians decide when further investigation is needed. Early identification is critical in guiding access to therapies that are most effective when initiated at earlier stages of disease." Cardiac Amyloidosis: An Urgent Clinical Challenge Cardiac amyloidosis is a serious and often underdiagnosed cause of heart failure, driven by abnormal amyloid protein deposits, either light chain (AL) or transthyretin-derived (ATTRwt and ATTRv), that stiffen the heart and impair its function. Symptoms often mimic those of other cardiac conditions, making diagnosis challenging. As many as two-thirds of cases may be missed clinically. 2-4 Early diagnosis is crucial, as new drug therapies such as Tafamidis are now available that can slow or halt disease progression.5 The condition is especially difficult to identify in patients with heart failure with preserved ejection fraction (HFpEF), a common but diagnostically complex subtype of heart failure. Studies suggest that an estimated 15% of HFpEF patients may have underlying cardiac amyloidosis,6 a hidden burden that often goes unrecognized. Study Design and Key Findings The clinical study evaluating EchoGo® Amyloidosis followed a rigorous two-phase process: Development & Optimization Phase: Conducted at Mayo Clinic using 9,786 patients, including 1,349 biopsy-confirmed cardiac amyloidosis (CA) cases and 1,263 matched controls, to train and refine the deep learning model. External Validation Phase: Conducted across 2,719 patients at 18 global centers, where the AI was independently tested against gold-standard diagnostic criteria The external validation cohort included a broad range of institutions including The University of Chicago Medicine, Columbia University Irving Medical Center, Brigham and Women's Hospital, University of Pennsylvania, The Ohio State University Wexner Medical Center, University of Washington, Hospital of the University of Occupational and Environmental Health (Japan), Instituto do Coração – INCOR (Brazil), ICBA and Centro Privado de Cardiología (Argentina), The University of Texas MD Anderson Cancer Center, NorthShore University HealthSystem, University of Virginia Medical Center, Boston University, MedStar Health Research Institute, University of Leicester (UK), and Beth Israel Deaconess Medical Center. EchoGo® Amyloidosis was trained using apical 4-chamber echocardiographic video clips and validated against established diagnostic benchmarks, including biopsy and Tc-PYP imaging. The AI demonstrated high diagnostic performance, achieving 85% sensitivity and 93% specificity, indicating its ability to detect cardiac amyloidosis accurately from a single routine echocardiogram.1 EchoGo® Amyloidosis demonstrated strong performance across all major subtypes of cardiac amyloidosis, with sensitivities of 84% for AL, 85% for ATTRwt, and 86% for ATTRv. In a high-risk subgroup of HFpEF patients with increased wall thickness, EchoGo® Amyloidosis maintained strong diagnostic performance, demonstrating potential utility in one of the most diagnostically challenging settings in cardiovascular care.1 In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac Amyloidosis Score (TCAS) and the Increased Wall Thickness Score (IWT). The AI model demonstrated an AUC of 0.921, significantly exceeding TCAS (0.74) and IWT (0.80) in diagnostic accuracy.1 Decision curve analysis showed EchoGo® Amyloidosis identified 36.4% more true positive cases and reduced unnecessary referrals by 6.9% compared to the next best method.1 "EchoGo® Amyloidosis achieved high diagnostic accuracy across a broad spectrum of patients and clinical environments," said Patricia A. Pellikka, MD, Vice Chair, Department of Cardiovascular Medicine, Mayo Clinic, and senior author of the study. "In our subgroup analysis of older adults with HFpEF, where diagnosis is particularly challenging, the model not only maintained strong performance but also significantly outperformed traditional clinical and transthoracic echo-based screening methods. These results highlight its potential to improve early detection, reduce diagnostic uncertainty, and enhance patient care." "Current approaches to detecting cardiac amyloidosis on echocardiography often rely on markers that are either unreliable in contemporary clinical settings or time-consuming to implement consistently across high-volume echocardiography laboratories," said Jeremy A. Slivnick, MD, co-author and Assistant Professor at The University of Chicago Medicine. "With its ability to provide fully automated detection of cardiac amyloidosis using a single apical 4-chamber view, EchoGo® Amyloidosis offers a practical alternative that can be seamlessly integrated into routine workflows without compromising diagnostic performance." EchoGo® Amyloidosis is FDA-cleared and currently in use across multiple U.S. centers. It is part of Ultromics' growing AI portfolio, which also includes EchoGo® Heart Failure, an FDA-cleared device designed to aid in the detection of HFpEF, reimbursable under Medicare and commercial payer pathways, including Category III CPT Code 0932T for outpatient use and NTAP (XXE2X19) coverage for inpatient settings. Both tools operate through the EchoGo® platform, delivering diagnostic and clinical decision support from standard echocardiographic video clips, while integrating seamlessly into existing workflows to enable timely, informed care. Ultromics continues to advance the field of cardiovascular imaging by integrating AI and deep learning into everyday practice. Its mission is to support earlier detection, smarter triage, and broader access to therapies that are most effective when introduced at earlier stages of disease. Full study: About Ultromics Ultromics is a pioneering health technology company founded at the University of Oxford, dedicated to transforming cardiac care through AI-powered echocardiography. Its flagship product under the EchoGo® platform applies advanced artificial intelligence to routine ultrasound scans, helping clinicians detect heart disease earlier and more accurately, starting with HFpEF and cardiac amyloidosis. With multiple FDA-cleared solutions, including the first AI screening tool for cardiac amyloidosis, Ultromics is setting new standards for real-world clinical integration of AI in cardiovascular imaging. The company collaborates with world-leading institutions, including Mayo Clinic, Pfizer, and Janssen Biotech, Inc. (a Johnson & Johnson Company), to accelerate innovation and improve outcomes for patients globally. Learn more at Website: References [1] Slivnick, Hawkes et al., Eur Heart J (in press).[2] González-López E, et al., Eur Heart J. 2015;36:2585–94.[3] Hahn VS, et al., JACC Heart Fail. 2020;8:712–24.[4] AbouEzzeddine OF, et al., JAMA Cardiol. 2021;6:1267–74.[5] Maurer MS, et al., N Engl J Med 2018;379:1007–16.[6] Hahn VS et al, JACC Heart Fail. 2020;8:712–724. Photo: View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
'This is a cultural gem for the city': Multi-million-pound museum refurb now complete
A NEW gallery documenting the history of film, television, and media opens its doors in the heart of Bradford today, and has been described as a 'cultural gem' for the city. It is hoped it will cement the National Science and Media Museum's reputation as a national attraction. The Sound and Vision Gallery includes priceless artefacts, including the camera that captured the first moving image, the fangs worn by Christopher Lee in the Hammer Dracula movies, and Stooky Bill – the dummy head that was the subject of the first television broadcast. The permanent gallery is the latest part of the museum's £6.8m refurbishment, and opens on the same day as another major city centre regeneration project, Darley Street Market. Both venues will be celebrating the openings with family events this weekend that are expected to attract huge crowds. Sound and Vision gives a spotlight to many artefacts that have spent years in the museum's storage, including a model dinosaur created by stop motion maestro Ray Harryhausen and a replica of the original xenomorph costume used in the first Alien film. Gallery project manager Yvonne Carmichael with a model of the Xenomorph costume used in Alien (Image: T&A) There is also an area dedicated to the Cottingley Fairies photos, which includes one of the original cameras used to take what became one of the most well-known hoaxes in history and which originated in a village just a few miles from the museum. The Cottingley Fairies section of the exhibition (Image: National Science and Media Museum) The refurbishment works have been supported by the National Lottery Heritage Fund. As well as more than 500 historic artefacts, there are a number of interactive areas and newly-created installations. The Telegraph & Argus was given a tour of the gallery ahead of today's launch. At the centre of Sound and Vision is 'Circus', a new art installation by Nayan Kulkarni that uses a series of cameras and screens to create a digital hall of mirrors. Nayan Kulkarni in the Circus installation (Image: T&A) People standing inside the installation can see their image distorted in a variety of different ways. Other installations allow visitors to be part of a Cottingley Fairy photo and become a sound engineer for a concert at Bradford's famous 1 in 12 Club. The first IMAX camera has been returned to the museum, and the hulking piece of equipment is one of the first exhibits in the gallery, reflecting the importance of IMAX to the history of the museum. In 1983, the museum opened the first IMAX cinema in the UK, with this camera used to project 'To Fly', a documentary about the history of flight. Louis Le Prince's single lens cine camera – which captured the world's first moving film footage in Leeds (Image: National Science and Media Museum) Other cameras in the exhibition include Louis Le Prince's single-lens cine camera, which captured the world's first moving film footage in Leeds, and the camera used by Herbert Ponting to document Captain Scott's Antarctic Expedition in 1910. John Logie Baird's ground-breaking experimental 'television apparatus' from 1926, which includes the Stooky Bill head that was the first image to be broadcast, is another hugely significant artefact in the gallery. Stooky Bill (Image: T&A) The fast-moving pace of technology means that some of the exhibits, such as an iPod and a television digibox, are not that far removed from the lives of many of the people who will visit the exhibition. Other exhibits include a Dalek from Doctor Who, a mixing desk used at festivals, and Shaun the Sheep models from Aardman Animation. Yvonne Carmichael, project manager for Sound and Vision, said the refurbishment works have seen many areas of the museum opened up, creating much more space. Exterminate! A Dalek in the Sound and Vision gallery (Image: National Science and Media Museum) She said: 'A lot of the items in this gallery were buried away or not very visible before, we've brought a lot out, things like the Cottingley Fairies artefacts. 'We hope this is something that people will travel to see.' Toni Booth, curator of film, said: 'One of the main focuses was to showcase more of the museum's collection, and the gallery was partly led by the objects we had. 'We've increased the number of objects we have on display three-fold compared to before. The vast majority of them were in our museum collection already, and it is great we've got so much space now. 'We've got around three-and-a-half million objects in our collection, so it is always a struggle to decide what to display.' Jo Quinton-Tulloch, director of the National Science and Media Museum, said: 'The galleries have been a true labour of love and collaboration, and they showcase our incredible collections in new and innovative ways. 'Our collections and the rich narratives they tell touch upon all our lives, from the first photographic negative and film footage to the advent of radio and television, and the power of sound technologies to bring us together. 'We have worked closely with a huge range of people to develop the galleries, ensuring these spaces work for everyone and that our visitors feel represented in the stories we tell.' Helen Featherstone, director, England, north at The National Lottery Heritage Fund added: 'The Sound and Vision galleries at the National Science and Media Museum are a cultural gem for the city, telling the story behind the photographic, film and sound technologies that have played such a big role in our lives.'
Yahoo
an hour ago
- Yahoo
Fungal infections are getting harder to treat
Fungal infections are getting harder to treat as they grow more resistant to available drugs, according to research published Wednesday in The Lancet Microbe. The study focused on infections caused by Aspergillus fumigatus, a fungus that is ubiquitous in soil and decaying matter around the world. Aspergillus spores are inhaled all the time, usually without causing any problems. But in people who are immunocompromised or who have underlying lung conditions, Aspergillus can be dangerous. The fungus is one of the World Health Organization's top concerns on its list of priority fungi, which notes that death rates for people with drug-resistant Aspergillus infections range from 47%-88%. The new study found that the fungus' drug resistance is increasing. On top of that, patients are typically infected with multiple strains of the fungus, sometimes with different resistance genes. 'This presents treatment issues,' said the study's co-author, Jochem Buil, a microbiologist at Radboud University Medical Centre in the Netherlands. Buil and his team analyzed more than 12,600 samples of Aspergillus fumigatus taken from the lungs of patients in Dutch hospitals over the last 30 years. Of them, about 2,000 harbored mutations associated with resistance to azoles, the class of antifungals used to treat the infections. Most of them had one of two well-known mutations, but 17% had variations of the mutations. Nearly 60 people had invasive infections — meaning the fungi spread from the lungs to other parts of the body — 13 of which were azole-resistant. In those people, nearly 86% were infected with multiple strains of the fungi, making treatment even more complicated. 'It is an increasingly complicated story and physicians may have trouble identifying whether or not they are dealing with a drug-resistant fungal infection,' said Dr. Arturo Casadevall, chair of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, who wasn't involved with the research. Before treating an Aspergillus fungal infection, doctors look for resistance genes that can give them clues about which drugs will work best. If someone is infected with multiple strains of the same type of fungus, this becomes much less clear-cut. Oftentimes, different strains will respond to different drugs. 'Azoles are the first line of treatment for azole-susceptible strains, but they do not work when a strain is resistant. For those, we need to use different drugs that don't work as well and have worse side effects,' Buil said, adding that some people will require treatment with multiple antifungal drugs at the same time. The findings illustrate a larger trend of growing pressure on the few drugs available to treat fungal infections — there are only three major classes of antifungal drugs, including azoles, that treat invasive infections, compared with several dozen classes of antibiotics. Resistance to such drugs is growing, and new ones are uniquely difficult to develop. Humans and fungi share about half of their DNA, meaning we're much more closely related to fungi than we are to bacteria and viruses. Many of the proteins that are essential for fungi to survive are also essential for human cells, leaving fewer safe targets for antifungal drugs to attack. 'The big problem for all of these fungal species is that we don't have a lot of antifungals,' said Jarrod Fortwendel, a professor of clinical pharmacy at the University of Tennessee Health Science Center, who was not involved with the research. 'Typically the genetic mutations that cause resistance don't cause resistance to one of the drugs, it's all of them, so you lose the entire class of drugs.' Further complicating matters, the vast majority of azole resistance in Aspergillus fumigatus stems from agriculture, which widely uses fungicides. The fungicides typically have the same molecular targets as antifungal drugs. Farmers spray them on crops, including wheat and barley in the U.S., to prevent or treat fungal disease. (The first instance of azole resistance was documented in the Netherlands, where antifungals are widely used on tulips.) Aspergillus fungi aren't the target, but exposure to the fungicides gives them a head start developing genes that are resistant to the targets, sometimes before an antifungal drug with the same target even hits the market. This was the source of the vast majority of the drug resistance analyzed in the study. Fortwendel noted that fungal resistance is increasingly found around the world. 'Basically everywhere we look for drug-resistant isotopes, we find them,' he said. 'We are seeing this azole drug-resistance happening throughout the U.S. Those rates will likely climb.' Any individual person's risk of having an azole-resistant Aspergillus fumigatus is low, Casadevall said. Infections typically affect people who are immunocompromised and amount to around a few thousand cases per year in the U.S., Casadevall said. While relatively uncommon, the bigger risk is the broader trend of drug-resistant fungal infections. 'The organisms that cause disease are getting more resistant to drugs,' he said. 'Even though it's not like Covid, we don't wake up to a fungal pandemic, this is a problem that is worse today than it was five, 10 or 20 years ago.' This article was originally published on